Belpointe Asset Management LLC acquired a new stake in Masimo Co. (NASDAQ:MASI – Get Rating) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 258 shares of the medical equipment provider’s stock, valued at approximately $38,000.
A number of other hedge funds have also made changes to their positions in MASI. Politan Capital Management LP purchased a new position in shares of Masimo in the 3rd quarter valued at about $656,234,000. Goldman Sachs Group Inc. boosted its position in shares of Masimo by 92.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 856,664 shares of the medical equipment provider’s stock valued at $111,940,000 after purchasing an additional 410,793 shares during the period. Farallon Capital Management LLC boosted its position in shares of Masimo by 195.9% in the 3rd quarter. Farallon Capital Management LLC now owns 577,000 shares of the medical equipment provider’s stock valued at $81,449,000 after purchasing an additional 382,000 shares during the period. Canada Pension Plan Investment Board boosted its position in shares of Masimo by 391.0% in the 3rd quarter. Canada Pension Plan Investment Board now owns 318,600 shares of the medical equipment provider’s stock valued at $44,974,000 after purchasing an additional 253,710 shares during the period. Finally, Worldquant Millennium Advisors LLC acquired a new stake in shares of Masimo in the 1st quarter valued at about $34,358,000. Hedge funds and other institutional investors own 87.67% of the company’s stock.
Analyst Ratings Changes
A number of analysts recently issued reports on the company. Stifel Nicolaus upped their target price on Masimo from $200.00 to $205.00 in a research report on Wednesday, May 10th. Raymond James increased their price objective on Masimo from $187.00 to $198.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 1st. StockNews.com assumed coverage on Masimo in a research report on Thursday, May 18th. They set a “hold” rating for the company. BTIG Research increased their price objective on Masimo from $195.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, April 17th. Finally, Piper Sandler increased their price objective on Masimo from $135.00 to $150.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $188.88.
Masimo Stock Performance
Masimo (NASDAQ:MASI – Get Rating) last released its earnings results on Tuesday, May 9th. The medical equipment provider reported $0.87 EPS for the quarter, beating the consensus estimate of $0.83 by $0.04. The firm had revenue of $565.00 million during the quarter, compared to analyst estimates of $557.87 million. Masimo had a return on equity of 19.32% and a net margin of 5.16%. The business’s quarterly revenue was up 85.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.93 earnings per share. As a group, analysts predict that Masimo Co. will post 4.76 earnings per share for the current fiscal year.
Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge.
- Get a free copy of the StockNews.com research report on Masimo (MASI)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.